Treating Depression Alternatively: BC Docs Use new treatments for depression

http://www.theglobeandmail.com/news/national/british-columbia/bc-doctors-learn-new-treatments-for-mood-disorders/article1492091/

Treating Depression

B.C. doctors learn new treatments for mood disorders

David Floody is a retired schoolteacher and now writer based in Tofino, B.C., where he uses a mental health training program and activities like running to battle effects of depression and seasonal affective disorder.David Floody is a retired schoolteacher and now writer based in Tofino, B.C., where he uses a mental health training program and activities like running to battle effects of depression and seasonal affective disorder. GEOFF HOWE FOR THE GLOBE AND MAIL

Program trains GPs to use coaching, self-help; Backers of innovative B.C. program hope it will lead to a revolution across Canada

1,231 total views, no views today

ANTIDEPRESSANTS: Murder-Suicide: Four Dead: Oregon

Paragraph three reads:  “The reports also indicates that Clackamas
County Sheriff’s Sgt. Jeffrey A. Grahn was taking antidepressants that
can trigger suicidal thoughts. Grahn also told witnesses he had a
couple of drinks before heading out on what would become a horrific
shooting rampage.”

Last three paragraphs read:  “He then grabbed Charlotte and hustled
her out a door near the bandstand. Once out in the alley, he pulled a
.40-caliber Glock 27 semiautomatic pistol from his sweatshirt pocket,
placed it against her head and fired.”

“Grahn then went back into the club and shot Schulmerich in the back
of the head, execution-style. He shot Hoffmeister in the face.”

“In the ensuing chaos, Grahn went back out in the alley, put the
pistol in his mouth and fired his fourth fatal shot.”

http://www.oregonlive.com/gresham/index.ssf/2010/02/post.html

Reports detail jealousy, suspicion behind Clackamas sergeant’s murder-suicide

By Rick Bella, The Oregonian

February 26, 2010, 6:15PM

GRESHAM — In the end, age-old jealousy and suspicion fueled an
off-duty sheriff’s sergeant’s blinding rage, culminating in a Feb. 12
triple murder-suicide at a Gresham lounge.

Complete report online
Gresham police released the complete report Friday into the Feb. 12
shooting rampage at the M&M Lounge.
That’s the conclusion that emerges from hundreds of pages of
investigative reports released Friday by Gresham police.

The reports also indicates that Clackamas County Sheriff’s Sgt.
Jeffrey A. Grahn was taking antidepressants that can trigger suicidal
thoughts. Grahn also told witnesses he had a couple of drinks before
heading out on what would become a horrific shooting rampage.

The reports, forming a two-inch-thick stack, detail interviews with 53
witnesses, seven members of victims’ families and eight other people.
In all, 40 police officers from Gresham, Troutdale, Fairview, Oregon
State Police and the Multnomah County Sheriff’s Office worked on the
reports.

 Also Friday, the Clackamas County Sheriff’s Office released a
separate report on a 2009 investigation of domestic abuse allegations
against the same sergeant.

The reports provide new information about the Grahns’ relationship and
Jeffrey Grahn’s actions.

According to interviews, Grahn and his wife, Charlotte M. Grahn, were
trying to repair what had been a volatile marriage. Grahn had moved
back to their Boring-area home after ending an affair with a Clackamas
County Courthouse employee.

Meanwhile, Grahn had tried to befriend other women through Facebook,
at one time carrying on sexually tinged conversations with a married
woman, all while telling friends he suspected his wife was cheating.

On Feb. 12, Charlotte Grahn and four friends went on a “ladies night
out” to Gresham’s Fourth Street Brewing Co. for dinner. Two friends
then went home, and Charlotte Grahn continued on to the M&M Lounge &
Restaurant with Kathleen Hoffmeister and Victoria Schulmerich to hear
some music.

Around 9:45 p.m., Jeffrey Grahn drove up to the M&M in a white pickup
and bulled his way into the crowded lounge and confronted his wife,
who was sitting at a table with Hoffmeister and Schulmerich. Grahn
then picked up a glass of beer and threw it in Schulmerich’s face,
yelling “What are you doing, bringing my wife into a place like
this?!”

He then grabbed Charlotte and hustled her out a door near the
bandstand. Once out in the alley, he pulled a .40-caliber Glock 27
semiautomatic pistol from his sweatshirt pocket, placed it against her
head and fired.

Grahn then went back into the club and shot Schulmerich in the back of
the head, execution-style. He shot Hoffmeister in the face.

In the ensuing chaos, Grahn went back out in the alley, put the pistol
in his mouth and fired his fourth fatal shot.

— Rick Bella


Thanks, Todd.
skype: retoddb
cel # 801.638.2844
hme 801.753.8031

Check out my web sites:
www.youtube.com/retoddb
www.LatterDayVegetarian.Com
www.CapacityDesign.Net – My Biz
www.DrugAwareness.Org – Save a life
Low prices on domain names and hosting: http://www.1and1.com?k_id=7093496
www.onforce.com/servicepro/67057
http://www.elance.com/retoddb

NOTICE: This email message is for the sole use of the intended
recipient(s) and may contain confidential and privileged information.
Any unauthorized review, use, disclosure or distribution is
prohibited. If you are not the intended recipient, please contact the
sender by reply email and destroy all copies of the original message.

701 total views, no views today

DEPRESSION MED: Murder-Suicide: Man Shoots three Deputies: Kills One

Paragraph five reads:  “Fresno Police Chief Jerry Dyer
said Friday that Liles
had been taking medication
for depression and probably took his own life with a gunshot to the
head.”

http://www.latimes.com/news/local/la-me-minkler27-2010feb27,0,2450243,full.story

A slow burn suddenly turns deadly in Minkler, Calif.

First there was a series of fires in the small town east of Fresno. Then
came the shootings. On Thursday, a shootout left a sheriff’s deputy dead and two
other law enforcement officers injured.

(Paul Sakuma /
Associated Press / February 26, 2010)

By Diana Marcum

February
27, 2010

Reporting from Minkler ­ Trouble had been brewing in tiny
Minkler, a Sierra foothills community about 20 miles east of Fresno, for months.
But residents never envisioned that it would end with two people — one a
sheriff’s deputy — dead and two other law enforcement officers
wounded.

Joel Wahlenmaier, 49, a veteran with the Fresno County Sheriff’s
Department who investigated homicides and other violent crimes, was killed in
Thursday’s gunfire. Deputy Mark Harris, 48, was injured.

Javier Bejar, a
Reedley police officer who responded to the call for backup in the minutes after
Wahlenmaier was shot, is on life support at Community Regional Medical Center in
Fresno and is not expected to survive.

The suspect, Ricky Ray Liles, 51,
died during the gun battle that erupted when authorities attempted to serve him
with a search warrant.

Fresno Police Chief Jerry Dyer said Friday that
Liles had been taking medication for depression and probably took his own life
with a gunshot to the head.

Liles had told his wife “that he would not go
to prison,” Dyer said at a news conference. “He would take the lives of several
officers before taking his own life.”

On Friday, what there is of Minkler
was cordoned off as a crime scene, helicopters buzzing overhead.

But
Minkler’s worries began about five months ago with small fires. A bunch of
leaves here, a patch of grass there.

“You’d come out and say, ‘How did
that tractor seat catch on fire?’ ” said rancher Jeff Rodenbeck,
51.

Eventually, a shed and a trailer burned. Then the shootings started.
Someone shot up the Minkler Cash Store six times since January. On Monday,
someone fired four bullets into Sally Minkler’s mobile home.

“Sally said
she bent over to get her cellphone and the bullet went right where her torso had
been,” said Mary Novack, who runs the Minkler Cash Store, the nerve-center and
commercial entirety of Minkler, a town so small it once was listed for sale on
EBay.

Residents were convinced the culprit was Liles, a former security
guard renting a mobile home on Minkler family property across from the
store.

“He was just your average pasty white guy with a bad back,” said
Jeff Butts, who grows grapes and plums along the Kings River.

“But when
you know all your neighbors, you look around and say, ‘Well, I know it’s not
Mary, and it’s not Charlie and it’s not Sally’ . . . and pretty soon everyone
came up with Liles,” Butts said. “He wasn’t friends with anyone. But no one ever
actually saw anything they could prove. Things were getting tense out
here.”

On Thursday morning, Novack was relieved when she saw law
enforcement vehicles pull up to Liles’ place. She called Butts and told him cops
were about to knock on Liles’ door.

“Hey, this guy is finally going down,
let’s go to the store and watch,” Butts said he told one of his
workers.

A small crowd gathered on the front porch of the general store,
which has held court in Minkler since 1920. They watched as a deputy kicked in
the door, shots were fired, an officer slumped, more law enforcement came and a
prolonged gun battle raged.

“I was stunned. I didn’t even get down,”
Butts said. “I kept thinking, ‘What are they doing? Those can’t be real
bullets.’ The cops are saying hundreds of rounds were fired, but it had to be
thousands.”

He was incredulous when a woman, later identified as Liles’
wife, Diane, and a dog emerged from the trailer. “I don’t see how anyone came
out of that alive,” Butts said.

Half a mile down the road, Rodenbeck
heard the first volley of shots. He loaded a pistol and rifle, and got his wife
and teenage daughter away from the house in case gunmen emerged from the woods
behind their home. Then he went to see what was going on.

When the bigger
gun battle began, he crouched inside his truck’s tire well.

“Look, this
is the country, gunfire is not a big deal, you hear it all the time. Someone’s
shooting at coyotes. Or skeet,” he said. “But this was a war zone. It sounded
like the cops had automatic rifles and they kept shooting. If you’d been here,
you would have hit the ground. It rocked this place. He killed a cop right in
front of them, and they don’t take lightly to that and I can’t say I blame
them.”

Rodenbeck moved to Minkler from Huntington Beach to raise his
family away from the city. He likes the beauty — “this is river bottom, green
all the time” — the quiet, and the fact that men such as Charles Minkler, the
great-grandson of Orzo Minkler, who founded the town in 1892, can still load
1,000 bales of hay. Minkler is in his 70s.

“Out here, men don’t get old.
They get beat up and wrinkled, but they don’t use canes,” Rodenbeck said. “They
have chores to do.”

But he was never under any illusion that violence
couldn’t touch this place.

“They say they used to hang people from that
tree over there,” he said. “Charlie can tell you about the bandits that used to
hide out in these hills. Different people have different reasons for wanting to
be out somewhere quiet.”

Novack, 54, recalls drug-dealing motorcycle
gangs in the 1970s. As a teenager, she glimpsed white-robed Ku Klux Klan members
burning crosses at the river’s edge.

“That’s a sight you never forget,”
Novack said. “It’s chilling.”

She looked around at the orchards in bloom,
snow-dusted peaks and sheepdogs trying to make friends with the
police.

“People are saying, ‘In Minkler? It’s so beautiful and quiet
there.’ But good and evil are everywhere,” she said. “Right in front of you.
Right next to each other all the time.”

metrodesk@latimes.com

Marcum is a
special correspondent for The Times.

The Associated Press contributed to
this report.

Copyright © 2010, The Los Angeles
Times

741 total views, no views today

Time Released Prozac for Dogs Approved in the UK

NOTE FROM Ann Blake-Tracy (www.drugawareness.org):

And who did they pay to “cook the books” on this research?!! Was the same
researcher who just plead guilty to falsifying research for GlaxcoThe initial
studies done by Lilly on dogs and cats demonstrated that the animals given

Prozac began to growl and hiss within days on the drug and the behavior
continued until several days AFTER withdrawal of the medication. Those results
would indicate a contraindication for Prozac being given to dogs as they
have for close to two decades now.

The only thing new with Reconcile, the name of the drug in the US, is
that it is a time release Prozac. All the time released change does is make
it FAR MORE difficult to withdraw from. If your dog happens to be a
rapid metabolizer then he/she will metabolize the drug faster than expected and
go into withdrawal before the next dose is given. And according to FDA warnings
you could have a dog that could be going into a withdrawal reactions
of suicide, hostility, or psychosis. . . . We need to do a survey to see
how many dogs are running in front of mack trucks and trains instead of just
chasing cars once they begin taking this medication. 🙂 🙂
🙂 . . . . Back to the seriousness of this issue, this is an
extremely dangerous way for dogs and humans or any other living creature to take
a drug!

____________________________________

At the time, Steve Connell, Eli Lilly’s manager of consumer services for
companion animal health, said that more than 10million US dogs exhibit strange
symptoms from being left alone too long. [Hmmmmm and how many humans and other
living creatures exhibit strange symptoms from being left alone too
long?!!!]

‘Lilly research shows that 10.7million, or up to 17 per cent, of US dogs
suffer from separation anxiety,’ he said. ‘We’re thrilled that our first product
for dogs can help restore the human-pet bond.’

He said research showed that 73 per cent of dogs taking Reconcile and
undergoing therapy showed better behaviour within eight weeks, compared to dogs

receiving therapy alone.

http://www.dailymail.co.uk/news/article-1252672/A-dogs-life-set-easier-day-pet-Prozac-treat-depression.html

A dog’s life set to get easier with once-a-day pet Prozac to treat
depression

By Daniel Martin
Last updated at 8:58 AM on 22nd February
2010

A dog version of the anti-depressant Prozac has been approved for sale to
British pet owners.

The one-a-day tablet, which tastes of beef, is said to help cure ‘canine
compulsive disorder’ and ‘separation anxiety’ brought on by owners’ long
absences during the day.

Symptoms include poor behaviour, whimpering or tail-chasing.

Spaniel looking sad

Down in the doggy dumps:
Once-a-day chewable tablet, which tastes of beef, has been launched in the US to
help dogs beat depression

The drug, called Reconcile, is also designed to curb the compulsive pacing,
chewing and dribbling which its makers claim is a result of depression brought
on by their owners’ long absences.

The anti-depressant Prozac has been used to cure compulsive behaviour in
humans, and works by increasing the brain’s levels of serotonin, a ‘happiness’
chemical.

Trials involving more than 660 mentally-disturbed pets in Europe and the US
produced improvements in behaviour within eight weeks.

Eli Lilly, the drug’s US manufacturer, said: ‘Treatment for companion animals
is a relatively new area for us.’

They point to research which shows that as many as 8 per cent of dogs suffer
from canine compulsive disorder.

Prozac

Pick me up: Prozac

Critics say dogs are now being diagnosed with ‘lifestyle’ illnesses so that
drugs can be marketed to treat them.

Roger Mugford, an animal psychologist, said: ‘Most breakthroughs in dog
behaviour are achieves by carrying a tidbit and using it wisely, not by
drugs.’

Reconcile has now been granted a license by the UK‘s Veterinary Medicines
Directorate.

However, it was first licensed in the US three years ago for separation
anxiety from being left alone for long periods.

The American Food and Drug Administration said it should be taken with
therapy to modify the dog’s behaviour – and should be taken by puppies as young
as six months.

At the time, Steve Connell, Eli Lilly’s manager of consumer services for
companion animal health, said that more than 10million US dogs exhibit strange
symptoms from being left alone too long.

‘Lilly research shows that 10.7million, or up to 17 per cent, of US dogs
suffer from separation anxiety,’ he said. ‘We’re thrilled that our first product
for dogs can help restore the human-pet bond.’

He said research showed that 73 per cent of dogs taking Reconcile and
undergoing therapy showed better behaviour within eight weeks, compared to dogs
receiving therapy alone.

The drug’s website says: ‘While you may not be familiar with canine
separation anxiety, you are probably familiar with its symptoms.

‘While you are gone, your dog may do one or several of the following: chew
destructively; bark or whine; inappropriate urination and/or defecation; drool;
pace; tremble; vomit – or worse.

‘Separation anxiety is a clinical condition in your dog’s brain. Your pet is
not a bad dog. Your pet’s behaviour is the result of separation
anxiety.’

In Britain, research for Sainsbury’s Bank in 2003 indicated that 632,000 dogs

and cats had suffered from depression in the previous year.

Nearly three times as many had suffered from behavioural problems which could
be linked to depression, such as attacking furniture.

Clare Moyles, Sainsbury’s pet insurance manager, said: ‘People are leading
more stressful lives and unfortunately this can have an adverse effect on the
health of our pets.

‘Cats and dogs can be very susceptible to their owner’s feelings and if they
sense that they are unhappy they can become agitated or depressed.’

Side effects of Reconcile can include lethargy, reduced appetite, vomiting,
shaking, diarrhoea, restlessness, excessive barking, aggression and seizures in
a small number of dogs.

1,212 total views, no views today

DEPT. of DEFENSE: Link Between Vet Suicides & Medications

Paragraph six of main article reads:  “Quality data
collection and analysis are critical components behind effective prevention
efforts. The Department made great strides over the last 12 months on gathering
critical information to understand the complexity of factors leading to suicide
and ways to prevent such tragedies from occurring within our communities. Data
collected by the DoD Suicide Event Report (DoDSER) tell us that we must continue
to educate our population and build programs, as there continue to be multiple
opportunities to intervene. For example, we are learning that 30% of individuals
who died by suicide communicated their potential self harm; 49% had been
seen in a medical/support clinic/program within 30 days of suicide;
and
26% sought broadly defined mental health resources.”

Paragraph 34 of main
article reads:  “In recent years, antidepressant medications,
particularly the use of Selective Serotonin Reuptake Inhibitors (SSRIs) have
been closely evaluated for the increased risk of suicide-related behaviors in
adolescents and young adults associated with their use
. In recognition

of this risk, the FDA’s requires a “black box” warning in the product labeling
of all antidepressant medications that advises clinicians to closely monitor any
worsening in depression, emergence of suicidal thinking or behavior, or unusual
changes in behavior, such as sleeplessness, agitation, or withdrawal from social
situations. Close monitoring is especially important during the first four weeks
of treatment. The FDA also recognizes that depression and other psychiatric
disorders are themselves associated with increased risks for
suicide.”

http://www.pennlive.com/newsflash/index.ssf?/base/national-15/12670299869190.xml&storylist=health

Link Between Medication And Veteran Suicide

2/24/2010, 10:27 a.m. EST
The Associated Press

(AP) ­ xfdte MEDICATION-AND-SUICIDE sked

TESTIMONY February
24, 2010 LOREE K. SUTTON, M.D. DIRECTOR U.S. DEPARTMENT OF DEFENSE HOUSE
VETERANS AFFAIRS LINK BETWEEN MEDICATION AND VETERAN SUICIDE Roll Call, Inc.
1255 22nd Street N.W. Washington, D.C. 20037 Transcript/Programming: Tel.
301-731-1728 Sales: Tel. 202-419-8500 ext 599 sales@cqrollcall.com www.cqrollcall.com Roll Call, Inc. is a private firm not
affiliated with the U.S. Government. Copyright 2010 by Roll Call, Inc.
Washington, D.C. U.S.A. All materials herein are protected by United States
copyright law and may not be reproduced, distributed, transmitted, displayed,
published or broadcast without the prior written permission of Roll Call, Inc.
You may not alter or remove any trademark, copyright or other notice from copies

of the content.Statement of Loree K. Sutton, M.D. Director, Defense Centers of
Excellence for Psychological Health and Traumatic Brain Injury Special Assistant
to the Assistant Secretary of Defense for Health Affairs U.S. Department of

Defense

February 24, 2010

Introduction

Chairman Filner, Mr.
Buyer, distinguished Members of the Committee; thank you for the opportunity to
appear here today to talk to you about the Department of Defense‘s (DoD) efforts
to reduce the number of suicides across our force.

On behalf of DoD, I
want to take this opportunity to thank you for your continued, strong support
and demonstrated commitment to our service members, veterans, and their
families.

Over the last nine years, a new era of combat emerged, where
counterinsurgency and asymmetric warfare are the norm. This shift continues to
place a great amount of strain on our most important resource, our service
members. Despite the operational challenges facing them and their families, they
remain incredibly resilient, motivated, and well-trained. The Department
recognizes the need to provide the resources and programs necessary to maintain
their resilience and motivation. Our core messages tell our service members and
their families that they are not alone; treatment works; the earlier the
intervention the better; and reaching out is an act of courage and
strength.

The Department also recognizes that the total number and rate

of suicides continue to rise and this is of deep concern at all leadership
levels. Today, I will share with the Committee our current efforts to reduce the
number of suicides across the Force, and the role of medication and
suicides.

Suicide has a multitude of causes, and no simple solution.
There are many potential areas for intervention, and it is difficult to pinpoint
the best approach because each suicide is unique. Recognizing this, DoD is
tackling the challenge using a multi- pronged strategy involving comprehensive
prevention education, research, and outreach. We believe in fostering a holistic
approach to treatment, leveraging primary care for early recognition and
intervention, and when needed, providing innovative specialty care. The areas of

focus to reduce risk include: (1) conducting data collection and analysis to
detect contributing risk factors; (2) facilitating partnerships across DoD,
federal agencies, and civilian organizations to increase collaboration and
communication; (3) reducing stigma and increasing access to resources to provide
needed care; and (4) using research to close gaps and identify best practices.
Data Surveillance

Quality data collection and analysis are critical
components behind effective prevention efforts. The Department made great
strides over the last 12 months on gathering critical information to understand
the complexity of factors leading to suicide and ways to prevent such tragedies
from occurring within our communities. Data collected by the DoD Suicide Event
Report (DoDSER) tell us that we must continue to educate our population and
build programs, as there continue to be multiple opportunities to intervene. For
example, we are learning that 30% of individuals who died by suicide
communicated their potential self harm; 49% had been seen in a medical/support
clinic/program within 30 days of suicide; and 26% sought broadly defined mental
health resources.

Historically, the Services used unique suicide
surveillance systems. In January 2008, the National Center for Telehealth and
Technology (T2), a Defense Centers of Excellence (DCoE) component center,
launched the DoDSER Annual Report. The DoDSER Annual Report was developed to
standardize data collection and reporting. Pulling data from all branches of the
military, it captures over 250 data-points per suicide with details, summaries,
and analyses of a wide range of potential contributing factors. DoDSER Annual
Report data include specific demographics, suicide event details, treatment, and
military history, among others. The variables are designed to map directly to
the Centers for Disease Control and Prevention’s National Violent Death
Reporting System to support direct comparisons between military and civilian
populations.

By standardizing data and reporting,
DoD tracks and analyzes suicide data and contributing risk factors proactively
to inform and improve future prevention, intervention, and treatment services.
The DoDSER Annual Report is revised annually based on input from the Services.
The data facilitate the review and evaluation of the effectiveness of suicide
prevention initiatives and their execution over time. DoDSER represents the
strides DoD has taken to better understand what some of the
underlying factors are for suicide. The Department uses this tool to inform
current efforts and initiatives. []

According to the Armed Forces
Medical Examiner System (AFMES), in January 2010 there were 24 confirmed

suicides, all in Regular Components within the DoD. In calendar year 2009, AFMES
reported that there were 312 confirmed suicides, with 286 confirmed in Regular
Components and 26 confirmed in the Reserve Components. Demographic risk factors
include: male, Caucasian, E-1 to E-4, younger than 25 years old, GED or less
than high school education, divorced, and in the Active Duty Component. Other
factors associated with suicide, which are consistent with data from civilian
populations, are: substance abuse, relationship issues, and legal,
administrative (Article 15), and financial problems. Although the impact of
deployment is still under investigation, a majority of suicides do not occur in
the theaters of operation. 16% of suicides occurred in Iraq or Afghanistan.
Despite the knowledge gained and data collected, it is important to resist
oversimplifying or generalizing statistics. Each suicide is as different as a
person is unique.

According to AFMES, there were 26 confirmed suicides in
calendar year 2009 among the Reserve Components, which include all Active Guard
and Reserves. Due to the unique nature of their service, there are challenges
associated with capturing all suicide completions, preparatory behavior and self
harm without intent to die among National Guard and Reserve populations when
they are not on active or activated status. To address this issue, DoD is
examining ways to utilize information gathered from existing tracking and
reporting systems including, but not limited to, insurance and benefit data. The
DoD continues to support National Guard and Reserve populations through numerous
initiatives to increase outreach, care, and resources on all fronts.

The
numbers also tell us that prevention is not enough, as 36% of military suicides

had a history of a mental disorder. The integrated efforts of prevention,
intervention, and treatment are essential to DoD’s approach to tackle the
challenge of suicide.

Facilitating Partnerships

Continued
collaboration with the Department of Veterans Affairs (VA) and other federal,
private, and academic organizations is a key part of DoD’s overall
strategy.

Conferences serve as dissemination and outreach platforms by
providing local and regional coordinators with innovative ideas to implement
within their communities and providing DoD and VA with the opportunity to gather
feedback on communities’ needs. The annual DoD/VA Suicide Prevention Conference
provides such a forum. With over 900 attendees, the 2010 conference shared
practical applications, results from research and pilot studies, guidance from
senior DoD and VA leaders on the way forward, and testimonies emphasizing the
importance of seeking help.

We work closely with our partners at the VA
to ensure that the transition out of service and into VA care is seamless and
that service members, veterans, and families receive the care they deserve. The
DCoE coordinates information and resources with VA’s National Suicide Prevention
Lifeline (1-800-273-TALK), and National Resource Directory. As part of this
partnership, DCoE worked with VA and the Substance Abuse and Mental Health
Services Administration (SAMHSA) in December of 2009 to modify the introductory
message on the Lifeline, so that callers are instructed to press “1” if they
are a United States military veteran or Active Duty Service Member (ADSM) or are
calling about one. This expansion increases the scope of services that are
available to ADSMs who may be in crisis.

Collaborative care is an example

of an immediate solution that DoD is aggressively implementing. According to
DoDSER data, 36 percent of completed suicides had a history of a mental health
condition. Providing mental health services in conjunction with primary care is
an important part of our prevention strategy because early detection and
intervention is a key to preventing suicide behaviors. Each Service is
developing collaborative care models based on recommendations from a National
Institute of Mental Health (NIMH) study. The DCoE collaborates with the Services
to integrate the best practices from these models to develop consistent
standards across DoD. DCoE is currently implementing a controlled trial study at
six sites and 18 clinics of collaborative primary care to inform future
efforts.

In August 2009, the DoD Suicide Prevention Task Force was
established under the purview of the Defense Health Board. The goal of the task
force is to provide recommendations to legislative and administrative bodies on
suicide prevention within the military.

The Department recognizes the
importance of eliminating the toxic threat of stigma by transforming its culture
from reactionary to a more proactive environment by engaging leadership to
encourage transparency, accountability, candor, and respect. The DoD is
promoting awareness among leaders and urging them to lead by example in matters
related to health and well-being. In addition, changes in policies and messages
to all levels help create a safe culture to seek help. One significant change
was the revision of question 21 on the questionnaire for security clearances on
whether a service member has sought mental or behavioral help in the past year.
DoD believes that service members should not have to deny themselves the care
they need and deserve out of fear of repercussions. Our efforts to combat stigma
will continue alongside our efforts to provide the best prevention, intervention
and treatment options.

Additionally, DoD is undergoing a cultural
transformation to push care closer to the service members and their families. An
emphasis on early intervention for antecedent issues such as post- traumatic
stress, depression, and substance abuse can help address needs before they
develop into bigger issues that could contribute to suicides. This population
based approach enables DoD to engage multiple audiences including peers,
families, units, and communities to support suicide prevention, risk reduction,
and overall health promotion. The Services also have programs to address needs
before they develop into issues that must be addressed in a specialty care
setting.

DCoE helps combat stigma through the Real Warriors Campaign, a
public education initiative that reinforces the notion that reaching out is a
sign of strength. Under the theme of “Real Warriors, Real Battles, Real
Strengths,” this effort provides concrete examples of service members who sought
care for psychological health issues and are maintaining a successful military
career. While primarily focused on stigma, the Real Warriors Campaign is
actively engaged in the fight against military suicide in a number of

ways:

The website prominently displays the National Suicide Prevention
Lifeline on every page;-Two video profiles of service members involved in the
campaign openly discuss their struggles with suicidal ideation from a position
of strength and optimism having reached out for care that is working; and-The
site allows service members, veterans, families and health professionals to
confidentially reach out to health consultants around the clock through the Real
Warriors Live Chat feature or by calling the DCoE Outreach Center.

The
Campaign’s message boards include numerous posts from service members who share
their coping strategies for dealing with suicidal ideation. The site includes
content that focuses on suicide prevention and substance abuse. Short,
documentary-style videos illustrate the resilience exhibited by service members,
their families, and caregivers.

Since the Real Warriors Campaign launched
in May 2009, the website, www.realwarriors.net,
saw more than 45,500 unique visitors from 127 countries, with more than 69,128
visits and 450,000 page views. The DoD believes that stigma can be defeated by
encouraging and supporting service members to reach out when help is
needed.

critical component of DoD’s strategy is advancing research. As
part of DoD’s research portfolio, the RAND Center for Military Health Policy
Research is reviewing and cataloguing suicide prevention programs across the
Services with recommendations for enhancements of current programs. The results
will be released March 2010 and disseminated to inform future program
development.

A pilot study that showed promise in the civilian sector is
the Caring Letters Program. In a randomized clinical trial, sending brief
letters of concern and reminders of treatment to patients admitted for suicide
attempt, ideation, or for a psychiatric condition was shown to dramatically
reduce the risk of death by suicide. In an effort to determine the applicability
to military populations, the National Center for TeleHealth and Technology (T2)
is piloting a program at Ft Lewis, Washington. The goals of the Caring Letters
Pilot are to (1) test the feasibility of expanding the program to other military
treatment facilities, (2) collect preliminary outcome data, and (3) evaluate the
method of letter transmittal (email vs. postal mail). Since its inception in
July 2009, 81 letters have been sent. Efforts are currently underway to plan a
multi-site randomized control trial.

Many programs are currently in place
to raise awareness among service members, train civilian providers supporting
our service members and communities, and increase leadership involvement in
behavioral health efforts. The programs are on all levels, from the national
level down into local communities. These initiatives, including programs that
provide face-to-face support or online support, demonstrate DoD’s multi-pronged
approach and commitment to ensuring service members and families have access to
the best resources. Some examples of these efforts are detailed
below:

Each Service has its own suicide prevention initiatives tailored
to its culture. In November 2007, DoD established the DCoE to offer a central
coordinating point for activities related to psychological health concerns and
traumatic brain injuries. DCoE focuses on the full continuum of care and
prevention to enhance coordination among the Services, federal agencies, and
civilian organizations. DCoE works to identify best practices and disseminate
practical resources to affected communities. In this effort, emphasis is placed
on building resilience, supporting recovery, and promoting reintegration to
ensure a comprehensive, multi-faceted, and proactive approach in promoting
health and wellbeing.

The Suicide Prevention and Risk Reduction Committee
(SPARRC), chaired by DCoE, provides a forum for inter-Service and VA partnership
and coordination. Members include Suicide Prevention Program Managers from the
Services and representatives from the National Guard Bureau, Reserve Affairs,
VA, Office of Armed Forces Medical Examiner, T2, Substance Abuse and Mental
Health Services Administration, and others. This committee is the main venue for
ensuring collaboration and consistency in system-wide communication related to
suicide, risk reduction policy initiatives, and suicide surveillance metrics
across the military. A SPARRC website is currently in development to serve as a
“clearinghouse” for suicide prevention information, contacts, innovative
approaches, and tools.

Additionally, the DCoE Outreach Center coordinates
with Military OneSource, accessible by phone at 1-800-342-9647. Licensed mental
health consultants are available to listen, answer questions, and refer callers
to a wide range of services 24 hours a day, seven days a week, 365 days a year.
Military OneSource provides services on a range of other topics including
education, relocation, and parenting.

Another DoD program that encourages
seeking care is inTransition, which provides a bridge of support for service
members while they are transitioning between health care systems or providers.
The program assigns credentialed “Supercoaches” on a one-on-one basis to service
members in transition. These “Supercoaches” provide support, encouragement, and
promote continued use of behavioral health services.

In an effort to
increase access to resources and align with modern communication platforms, DoD
is harnessing technology and social media tools. Afterdeployment.org, an
interactive website developed by T2, provides service members and families
behavioral health information using an anonymous platform. This mental wellness
resource is designed to help service members and families manage the challenges
faced after a deployment. In addition, Afterdeployment.org launched a series of

free podcasts, available on iTunes, discussing a variety of mental health issues
affecting service members and families. Since the rollout in August 2008,
Afterdeployment.org has seen 86,083 visits to its website. Afterdeployment.org
is currently developing both a mobile version of the site and a mobile
application. The portability will allow access to resources regardless of
location.

Telebehavioral health refers to use of telecommunications and
information technology for clinical and non-clinical behavioral health care
services. Telebehavioral health may include the use of videoconferencing,
web-based cameras, email and telephone. T2 is exploring ways to supply timely
telebehavioral health services to service members in theater and during health
screenings immediately upon return to the continental United States. The use of

technology provides service members and their families access to psychological
health care even in the most extreme and/or remote circumstances. Medication and
Suicide Risk

The Department supports the use of psychopharmacological
treatments as a key component of mental health care. Scientific evidence over
the past several decades points to the role of medications in limiting the
severity and duration of illness as well as for preventing relapses and
recurrences. These findings have been translated into recommendations for
clinicians in the VA-DoD Clinical Practice Guidelines for Major Depressive
Disorder, Post-Traumatic Stress Disorder, Psychoses and Substance Use Disorder.
These guidelines are updated periodically as required to reflect the most
current knowledge concerning each of these conditions. Recognizing that all

medications carry potential risks as well as benefits, clinicians must exercise
their judgment in applying these guidelines and determining the most effective
use of medications, other therapies which include Cognitive Behavioral Therapy,
Cognitive Processing Therapy and/or Prolonged Exposure treatment, or a
combination of medication and therapy. Therapy must be monitored, with careful
attention to diagnosis, dosing, clinical response and potential adverse
events.

In recent years, antidepressant medications, particularly the use
of Selective Serotonin Reuptake Inhibitors (SSRIs) have been closely evaluated
for the increased risk of suicide-related behaviors in adolescents and young
adults associated with their use. In recognition of this risk, the FDA’s
requires a “black box” warning in the product labeling of all antidepressant

medications that advises clinicians to closely monitor any worsening in
depression, emergence of suicidal thinking or behavior, or unusual changes in
behavior, such as sleeplessness, agitation, or withdrawal from social
situations. Close monitoring is especially important during the first four weeks
of treatment. The FDA also recognizes that depression and other psychiatric
disorders are themselves associated with increased risks for
suicide.

Accordingly, the Department uses multiple tools to address the
identified risk for antidepressant as well as other medications, as scientific
evidence reaches the threshold for action. These methods include dissemination
of safety alerts to clinicians, patient information sheets, pharmacy monitoring
for harmful combinations of prescribed medications, adherence to The Joint
Commission standards governing medication reconciliation, compliance with the
reporting of adverse events, increasingly sophisticated use pharmacotherapeutic
analysis as well as training and education programs in evidence-based modalities
reflecting the most current clinical practice guidelines.

The DoDSER data
base, while still maturing, provides an unprecedented repository of Service
suicide surveillance data that will continue to inform our efforts. Further, we
look forward to the payoff from continued research investments.

Way
Forward

Suicide is a problem that needs solutions now. DoD is focused on
rapidly translating best practices into applicable tools for service members and
families. At the same time, DoD continues to improve on collaborative
relationships across the Services and with national experts, collecting data,
and in research efforts that will accelerate improvements in current services
and programs as well as spur new innovations. In addition, DoD will also
continue to evolve and leverage our population-based system to push innovations
in prevention and care toward the service member and family.

DoD’s
current initiatives to address the challenges placed on service members and
their families are progressing, but we recognize that there is still much to be
done. In order to build on our current efforts and successfully shift to a model

of population-based care, we identified the following areas of additional
focus.

An issue of increasing concern is suicides of military family
members and how to support surviving families. At this point in time, DoD does
not track suicides of military family members. However, DoD recognizes the
importance of engaging and supporting this population, as their sacrifices
deserve our recognition. The DoD Suicide Prevention Task Force met this year
with surviving families at the Tragedy Assistance Program for Survivors (TAPS)
Seminar. The DoD Task Force will provide recommendations to the Secretary of

Defense and Congress. Efforts will be focused on increasing outreach to
families; providing families with more education and training to recognize the
signs of suicidal behavior and where to seek help; and supporting families after
a suicide event. In addition, for calendar year 2010, SPARRC partnered with TAPS
to form a sub-committee to identify additional needs of families and to
recommend concrete solutions.

Postvention, which refers to all activities
and response after a suicide event, is another area of growing attention. The
goals of postvention include: (1) promote healing, (2) reduce risk of contagion,
and (3) identify those at risk and connect them to help. Postvention is also
viewed as a form of prevention for survivors. This year, DoD will work with the
Services to promote consistent postvention protocols across
programs.

Connect/Frameworks Suicide Postvention Program is a civilian
program that utilizes evidenced supported protocols to promote an integrated
community based response to suicides. Postvention protocols and guidelines
include topics such as discussing cause and method of death; how to address
needs of families; memorial service activities; and media coverage and
messaging.

In addition to prevention, intervention, and treatment, DoD is
shifting attention to increasing resilience. DoD promotes a holistic approach
that optimizes the physical, psychological, and spiritual components of the
human condition. The DoD is also piloting resilience programs in military
settings to determine applicability and effectiveness within military
populations. While the impact of deployment on suicide is still under
investigation, it cannot be denied that an era of high operational tempo and
persistent conflict increases pressure on our warriors. A comprehensive approach
to enhancing resilience actively confronts the increasing stressors service
members face in this environment.

2010 will also provide DoD further
opportunities to demonstrate a public health model of prevention, by supporting
peer-to-peer programs in the Services and continuing to increase the number of

mental health providers in communities. DoD is actively engaged in hiring more
mental health providers and providing them with quality and continued training.
Conclusion

Through our united and concerted efforts, we can continue
making a change for the better. DoD recognizes the need to provide the resources
and programs necessary to maintain the resilience and motivation of our service
members and families. We will continue to emphasize education as we deliver our
core messages. “You are not alone; treatment works; the earlier the intervention
the better; and reaching out is an act of courage and strength.”

We are
devoted to this effort and will continue to work aggressively to prevent the
unnecessary loss of life.

With the Committee’s continued assistance and
support, we will ensure our brave men and women in uniform and their families
have access to the resources they require.

On behalf of the DoD, thank
you for the opportunity to highlight these vital issues. I look forward to your
questions.

622 total views, no views today

Sen. Grassley Investigates Lilly/WebMD link Reported by Washington Post

Dear Friends and Colleagues,

Freelance writer and
cartoonist Martha Rosenberg has worked diligently to reveal the conflict of
interest in many of the pharma/medical  situations.

Please
rate this column. The rating buttons are at the top of the page after you click
on this link and are into the site. There is no
requirement to register or log-in so it should take only a few
seconds.

Thank you.

Rosie Meysenburg
Moderator:
www.SSRIstories.com

http://www.opednews.com/articles/GrassleyInvestigates-Lill-by-Martha-Rosenberg-100224-629.html

Grassley Investigates Lilly/WebMD link Reported by Washington
Post

By Martha Rosenberg (about the
author
)     Page 1 of 2 page(s)

opednews.com Permalink

For OpEdNews: Martha Rosenberg – Writer

It is
not too hard to find evidence of links between WebMD and drug giant Eli
Lilly.

A 2002 article on the gigantic medical site about pain and
depression says “Lilly is a WebMD Partner,” and an advertising award in 2004
went to the FCB “client” Eli Lilly & Co./WebMD–not clients.

Banner
and skyscraper ads for Lilly‘s blockbuster antidepressant Cymbalta on WebMD‘s
home page never seemed to yield to other advertisers in 2009–and the Washington

Post reported Lilly and WebMD to be partners in 2000.

Now Sen. Charles
Grassley (R-Iowa), ranking Republican on the Senate Finance Committee, is
investigating financial ties between Lilly and WebMD Health Corp because of a

WebMD TV ad exhorting people to undergo a Lilly depression screening.

You
can joke about the need to tell people they are depressed–do people need to be
told they have a headache?–but pharma’s screening ruse to recruit new
patient pools for the volatile drugs among teens, adolescents and new mothers is
not funny.

3,500 news articles about antidepressant linked violence
appear on the web site, SSRIstories.com, including 700 murders, 200
murder-suicides, 51 school shooting incidents and 54 postpartum depression cases
since 1989.

In addition to WebMD, WebMD Health Corp. includes the web
sites Medscape, MedicineNet, eMedicine, eMedicine Health, RxList, theHeart.org,
and drugs.com. Original partners and investors says the Washington Post included
“Microsoft, DuPont, Rupert Murdoch’s News Corp. (and his Fox TV networks),
Silicon Graphics and Netscape founder Jim Clark, drug maker Eli Lilly, and EDS,
the computer services company founded by H. Ross Perot.”

Lilly is not the
only pharma company receiving unmarked product placement on WebMD.

Last
summer, a video featured a woman patient confessing she was fearful of life
while a voice over said she needed treatment for “general anxiety disorder” and
the camera showed bottles of Forest Pharmaceuticals’ antidepressant
Lexapro moving down the manufacturer’s assembly line
. Get it? No disclaimer
on the video or “sponsored content” appeared.

Another unsponsored WebMD

video last summer urged people on antidepressants to remain on their therapy
“despite side effects” and a third suggested women concerned about cancer, heart
attack and stroke risks of postmenopausal hormone therapy should continue their
treatment at lowered doses. Hang in there, valued customers.

A search for
Wyeth (now Pfizer) antidepressant Effexor a few months ago on WebMD elicited a
JAMA study finding Effexor superior to other antidepressants by a Wyeth funded
second author, Graham Emslie, MD. Effexor was the drug Andrea Yates took when
she drowned her five children in 2001, a case found on
SSRIstories.

Questions about conflict of interest have surfaced at
WebMD‘s Medscape too which administers many of the lucrative drug company
sponsored continuing medical education [CME] courses in the US which doctors
must complete to keep their state licenses.

Last year psychiatrist Daniel
Carlat, MD–who recounts his adventures as a Wyeth paid Effexor promoter in the
New York Times magazine–writes that he received, as a member of Medscape, an
envelope with “a brochure from Forest Laboratories advertising Lexapro, and
nothing else. It was creepy, like Invasion of the Body Snatchers.”

While
Lilly is known for launching the SSRI antidepressant revolution with Prozac,
Cymbalta does much of the heavy lifting now with worldwide sales of $3.075
billion in 2009.

Many remember Cymbalta as the drug 19-year-old healthy
clinical volunteer Traci Johnson killed herself on, during trials on the Lilly

campus in 2004–soon after FDA investigations into suicide/antidepressant
links.

Traci had no depression history said Rev. Joel Barnaby, a
spokesman for the Johnson family, who called Lilly‘s decision to proceed with
Cymbalta’s launch as scheduled “offensive” posturing.

Five others
suicides occurred during Cymbalta clinical trials, said the FDA and twice the
rate of suicide attempts were seen in women prescribed the drug for stress
urinary incontinence–also patients with no depression to blame.

Others
remember Cymbalta as the drug Carol Anne Gotbaum, daughter-in-law of New York
City Public Advocate Betsy Gotbaum, was taking during her macabre death in
police custody at the Phoenix’s Sky Harbor airport in 2007.

But now Lilly
and WebMD are pushing Cymbalta for pain since it was approved for
fibromyalgia in 2008. “Across cultures, patients who complain of pain tend to be
depressed,” says the 2002 article which calls WebMD and Lilly partners, a
finding from a “huge international study by Prozac manufacturer Eli Lilly and
Company.”

“Could your muscle aches be related to depression?” hawks WebMD

text under the heading, “Recognizing the Symptoms of Depression.” Next to it is
a picture of a depressed women with arrows pointing to the pain in her head and
neck, chest and stomach, arms and hands, legs and feet and of course
back.

“Print out this symptom diary, and fill it out. Then take it to
your doctor to discuss what may be causing your symptoms.”

This content,
we’re told, is “selected and controlled by WebMD‘s editorial staff” but “funded
by Lilly USA.”


Martha Rosenberg is
columnist and cartoonist based in Chicago I

727 total views, no views today

Ban Avandia & Save Per Month 300 from Heart Failure & 500 from Heart Attacks!

The reports, obtained by The New York Times, say that if every diabetic now taking Avandia were instead given a similar pill named Actos, about 500 heart attacks and 300 cases of heart failure would be averted every month because Avandia can hurt the heart. Avandia, intended to treat Type 2 diabetes, is known as rosiglitazone and was linked to 304 deaths during the third quarter of 2009.
“Rosiglitazone should be removed from the market,” one report, by Dr. David Graham and Dr. Kate Gelperin of the Food and Drug Administration, concludes. Both authors recommended that Avandia be withdrawn.

Avandia was once one of the biggest-selling drugs in the world. Driven in part by a multimillion-dollar advertising campaign, sales were $3.2 billion in 2006. But a 2007 study by a Cleveland Clinic cardiologist suggesting that the drug harmed the heart prompted the F.D.A. to issue a warning, and sales plunged.

http://blogs.healthfreedomalliance.org/blog/2010/02/22/once-again-big-pharma-lies-and-people-die/

Feb

22

Once Again Big Pharma Lies And People Die

Filed Under Big Medicine, Big Pharma, FDA, Medical Maiming

Bush lied people died, whoops wrong website. Big Pharma lied people died. There that’s better. In what should be a shocking report but now is all to common, Glasko Smith Kline got caught lying about the dangers of their blockbuster diabetes drug named Avandia. Health Freedom Alliance assumes the penalty will be a small fine and increased campaign contributions. Hundreds of people taking Avandia, a controversial diabetes medicine, needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market.

The reports, obtained by The New York Times, say that if every diabetic now taking Avandia were instead given a similar pill named Actos, about 500 heart attacks and 300 cases of heart failure would be averted every month because Avandia can hurt the heart. Avandia, intended to treat Type 2 diabetes, is known as rosiglitazone and was linked to 304 deaths during the third quarter of 2009.

“Rosiglitazone should be removed from the market,” one report, by Dr. David Graham and Dr. Kate Gelperin of the Food and Drug Administration, concludes. Both authors recommended that Avandia be withdrawn.

The internal F.D.A. reports are part of a fierce debate within the agency over what to do about Avandia, manufactured by GlaxoSmithKline. Some agency officials want the drug withdrawn because they believe there is a safer alternative; others insist that studies of the drug provide contradictory information and that Avandia should continue to be an option for doctors and patients. GlaxoSmithKline said that it had studied Avandia extensively and that “scientific evidence simply does not establish that Avandia increases” the risk of heart attacks.

The battle has been brewing for years but has been brought to a head by disagreement over a new clinical trial and a Senate investigation that concluded that GlaxoSmithKline should have warned patients earlier of the drug’s potential risks.

Avandia was once one of the biggest-selling drugs in the world. Driven in part by a multimillion-dollar advertising campaign, sales were $3.2 billion in 2006. But a 2007 study by a Cleveland Clinic cardiologist suggesting that the drug harmed the heart prompted the F.D.A. to issue a warning, and sales plunged. A committee of independent experts found in 2007 that Avandia might increase the risk of heart attack but recommended that it remain on the market, and an F.D.A. oversight board voted 8 to 7 to accept that advice.

Hundreds of thousands still take the medicine, although some top endocrinologists say they have sworn off the drug.

Since 2007, more studies have been done. In a December 2009 internal memorandum, Dr. Janet Woodcock, director of the F.D.A.’s drug center, wrote that “there are multiple conflicting opinions” about Avandia within the agency, and she ordered officials to assemble another advisory committee, expected this summer, to reconsider whether the drug should be sold.

“I await the recommendations of the advisory committee,” the agency’s commissioner, Dr. Margaret Hamburg, said Friday night. “Meanwhile, I am reviewing the inquiry made by Senators Baucus and Grassley and I am reaching out to ensure that I have a complete understanding and awareness of all of the data and issues involved.”

The bipartisan multiyear Senate investigation — whose results are expected to be released publicly on Monday but which were also obtained by The Times — sharply criticizes GlaxoSmithKline, saying it failed to warn patients years earlier that Avandia was potentially deadly.

“Instead, G.S.K. executives attempted to intimidate independent physicians, focused on strategies to minimize or misrepresent findings that Avandia may increase cardiovascular risk, and sought ways to downplay findings that a competing drug might reduce cardiovascular risk,” concludes the report, which was overseen by Senator Max Baucus, a Montana Democrat, and Senator Charles E. Grassley, an Iowa Republican.

Mr. Baucus said of the report, “Patients trust drug companies with their health and their lives, and GlaxoSmithKline abused that trust.”

In response, GlaxoSmithKline said that it disagreed with the Senate investigation’s conclusions. The company said that it could not comment on internal F.D.A. documents but that “the official ruling from F.D.A. is that Avandia remain on the market.”

In the wake of the controversy, agency officials ordered GlaxoSmithKline to undertake a study comparing how many heart attacks, strokes and heart-related deaths occur among patients given either Avandia, Actos or a placebo. Studies suggest that Actos, made by Takeda, lowers blood sugar as well as Avandia but without hurting the heart as much.

But Dr. Graham and Dr. Gelperin, working in the F.D.A.’s office of surveillance and epidemiology, argued in two separate internal reports that the new GlaxoSmithKline study, called TIDE, is “unethical and exploitative” because patients given Avandia face far greater risks than those given Actos, with no promise of any additional benefit. The trial may include patients who have had heart attacks or chest pains even though some foreign drug authorities have warned against Avandia’s use by precisely such patients, the reports note.

“Although the proposed TIDE trial is motivated by a desire for definitive answers regarding the cardiovascular safety of the drug rosiglitazone, the safety of the study itself cannot be assured and is not acceptable,” one of the reports concludes.

These concerns, in internal reports dated October 2008 but not made public until now, were later overruled by other agency officials, and GlaxoSmithKline is currently enrolling patients in the TIDE trial. The trial is not expected to be completed until 2020, although the company is hoping to report some results to the F.D.A. by 2014. The company’s patent on Avandia expires in 2012, and generic versions will probably swallow most remaining profits.

http://www.nytimes.com/2010/02/20/health/policy/20avandia.html?hp

639 total views, no views today

Medical examiner confirms death of 9-yr-old Colony, TX boy was

NOTE FROM Ann Blake-Tracy (www.drugawareness.org):

This suicide is much too similar to little Gabriel Myers’ (7) suicide
in Florida last year – while in the custody of CPS! He too was on
similar medications when he impulsively hung himself with a shower
hose in the bathroom.

Both types of medications have an FDA black box warning for suicide
for this age group. WHY?!!! Want to talk about him being exposed to
something toxic? This is it! Why as a society do we allow this to
continue?!!! Why is it okay for doctors to give patients drugs that
could cause suicide?

Here is the warning given for Strattera which is prescribed for ADHD.
[And a similar warning was given to all antidepressant and mood
stablizing medications (which Montana was also taking).]

9/05 From Web MD: “The FDA is advising health care providers and
caregivers that children and adolescents being treated with Strattera
should be closely monitored for worsening of symptoms as well as
agitation, irritability, SUICIDAL THINKING OR BEHAVIORS, and unusual
changes in behavior, especially during the initial few months of
therapy or when the dose is changed (either increased or decreased).”

“THIS MONITORING SHOULD INCLUDE DAILY OBSERVATION BY FAMILIES AND
CAREGIVERS AND FREQUENT CONTACT WITH THE PHYSICIAN, says the FDA.”
[Emphasis added]

What kind of close monitoring is this when he hangs himself in a
nurses office?! Why did none of the professionals working with Montana
withdraw him from the medications which had been producing these
suicidal thoughts for some time BEFORE he lost his life? I see these
FAR TOO OFTEN and the children are getting younger and younger as
those who should be caring for them ignore these strong FDA warnings
that are the next closest thing there is to banning a group of drugs!

Ann Blake-Tracy, Executive Director,
International Coalition for Drug Awareness

http://www.dallasnews.com/sharedcontent/dws/dn/latestnews/stories/021710dnmetlancesuicide.12e83ee14.html?so=TimeStampAscending&ocp=5#slcgm_comments_anchor

Medical examiner confirms death of 9-year-old Colony boy was suicide

11:13 PM CST on Thursday, February 18, 2010

By WENDY HUNDLEY/The Dallas Morning News
whundley@dallasnews.com

The Tarrant County medical examiner’s office ruled Thursday that a
9-year-old boy from The Colony committed suicide.

Montana Lance

The determination rules out speculation that Montana Lance’s death was
an accident.

Montana was found hanging in a bathroom at Stewart’s Creek Elementary
School around 1 p.m. Jan. 21. He was taken to Baylor Medical Center at
Carrollton, where he was pronounced dead.

Lt. Darren Brockway of The Colony police said the medical examiner’s
ruling is consistent with police conclusions about the death.

“He’d gotten in trouble at school and panicked,” Brockway said. “He
just felt there was no other way out.”

There had been speculation that Montana watched a television show
about teen suicide the night before his death and was copying what he
saw with no real intention to kill himself.

“We ruled that out as an option after talking to his parents,”
Brockway said. “He didn’t watch that show.”

Also Online

01/25/10: Friends, family stunned by apparent suicide of 9-year-old boy

Link: Leave your condolences for the family of Montana Lance

Still, experts say children as young as Montana may not fully
comprehend the consequences of their actions. A suicidal act may be a
spur-of-the-moment act, like an outburst or a tantrum, they say.

“It was more of a conscious decision he made in a moment of high
anxiety,” Brockway said.

A spokesman for the Lance family could not be reached for comment
Thursday. A police report says Montana’s father had insisted the death
was accidental.

Brockway said Montana had been upset on the day of his death after he
was sent to the office for misbehaving in class. He locked himself in
the school nurse’s restroom and didn’t come out.

After about 10 minutes, the nurse got a key to open the door and found
the child unconscious.

Montana had attached the buckle of a brown cloth belt to a hook of a
device used to help disabled people use the restroom, according to a
police report. He was found with the belt around his neck with his
feet off the floor. Police found no notes or messages.

He had been taking medication for mood swings and for attention
deficit hyperactivity disorder, and had been having suicidal thoughts
for about two years, the police report states.

In 2007, Montana’s parents, Jason and Debbie Lance, sought treatment
for their son for ADHD.

In 2008, they told the doctor that the boy had been talking about
committing suicide, and he was referred to a psychiatrist, according
to the police report.

After Montana’s death, Child Protective Services opened an
investigation to determine whether abuse or neglect were contributing
factors.

That investigation has not been completed, but the family’s other two
children have not been removed from the home, CPS spokeswoman Marissa
Gonzales said.

Gonzales said CPS has had no prior involvement with the Lances and
routinely investigates child fatalities.

With the medical examiner’s ruling, police plan to close their
investigation with no charges filed, Brockway said.

939 total views, no views today

SEROQUEL: Man accused of drugging, raping Orem woman – UT

NOTE FROM Ann Blake-Tracy (www.drugawareness.org): ALWAYS KEEP IN
MIND THAT THERE IS LITTLE DIFFERENCE IN THESE ATYPICAL ANTIPSYCHOTICS AND SNRI
ANTIDEPRESSANTS. THEY ARE VERY POWERFUL SEROTONIN REUPTAKE INHIBITORS INHIBITING
MULTIPLE SEROTONIN RECEPTORS!!! AND ON TOP OF THAT ARE SEROTONIN AGONISTS
AS WELL.

Police say the drug Christensen gave to the victim was a 300 mg
Seroquel, a medication for which he has prescription. The drug is
given to bipolar disorder and is an antipsychotic
medication.

Police say one of the side effects of the drug is
impaired thinking and reactions, and that people should also avoid alcohol
when taking it.

Man accused of drugging, raping Orem woman

Last Update:
2/18 3:20 pm

OREM, Utah (ABC 4 News) – Police say a Utah
County man drugged a woman he met at a bar and raped her.

Police say on
Friday February 12, Orem officers responded to a report of a rape that
had been reported from the night before.

Police say the victim
is a 24-year-old woman from southwest Orem.

According to
police, the victim met 26-year-old Jason Christensen at a bar in
Provo.

Police say both the suspect and alleged victim had been
drinking and went back to her apartment when Christensen gave her a pill to help
her sleep.

After taking the pill, police say the only thing the
victim remembered was waking up for a moment while the
suspect was sexually assaulting her.

After that, police say the
victim doesn’t remember anything for several hours until she woke up and
was undressed.

According to police, Christensen gave the victim the
pill at about 3:00 a.m. on the 11th and she didn’t wake up until 11:00 a.m. the
same day.

Police say the drug Christensen gave to the victim was a
300 mg Seroquel, a medication for which he has prescription.
The drug is given to bipolar disorder and is an
antipsychotic medication.

Police say one of the side effects

of the drug is impaired thinking and reactions, and that people should also
avoid alcohol when taking it.

Detectives caught up with Jason on
Wednesday at the City Center Motel in Provo where he was staying. He was
arrested and charged with Rape and Distribution of a
Prescription.

—-Information from: Orem
Police

1,098 total views, no views today

Medical examiner confirms death of 9-yr-old Colony, TX boy was suicide

NOTE FROM Ann Blake-Tracy (www.drugawareness.org):

This suicide is much too similar to little Gabriel Myers’ (7) suicide in Florida last year – while in the custody of CPS! He too was on similar medications when he impulsively hung himself with a shower hose in the bathroom.

Both types of medications have an FDA black box warning for suicide for this age group. WHY?!!! Want to talk about him being exposed to something toxic? This is it! Why as a society do we allow this to continue?!!! Why is it okay for doctors to give patients drugs that could cause suicide?

Here is the warning given for Strattera which is prescribed for ADHD. [And a similar warning was given to all antidepressant and mood stablizing medications (which Montana was also taking).]

9/05 From Web MD: “The FDA is advising health care providers and caregivers that children and adolescents being treated with Strattera should be closely monitored for worsening of symptoms as well as agitation, irritability, SUICIDAL THINKING OR BEHAVIORS, and unusual changes in behavior, especially during the initial few months of therapy or when the dose is changed (either increased or decreased).”

“THIS MONITORING SHOULD INCLUDE DAILY OBSERVATION BY FAMILIES AND CAREGIVERS AND FREQUENT CONTACT WITH THE PHYSICIAN, says the FDA.” [Emphasis added]

What kind of close monitoring is this when he hangs himself in a nurses office?! Why did none of the professionals working with Montana withdraw him from the medications which had been producing these suicidal thoughts for some time BEFORE he lost his life? I see these FAR TOO OFTEN and the children are getting younger and younger as those who should be caring for them ignore these strong FDA warnings that are the next closest thing there is to banning a group of drugs!

Ann Blake-Tracy, Executive Director,
International Coalition for Drug Awareness

http://www.dallasnews.com/sharedcontent/dws/dn/latestnews/stories/021710dnmetlancesuicide.12e83ee14.html?so=TimeStampAscending&ocp=5#slcgm_comments_anchor
Medical examiner confirms death of 9-year-old Colony boy was suicide

11:13 PM CST on Thursday, February 18, 2010

By WENDY HUNDLEY/The Dallas Morning News
whundley@dallasnews.com
The Tarrant County medical examiner’s office ruled Thursday that a 9-year-old boy from The Colony committed suicide.

Montana Lance
The determination rules out speculation that Montana Lance’s death was an accident.

Montana was found hanging in a bathroom at Stewart’s Creek Elementary School around 1 p.m. Jan. 21. He was taken to Baylor Medical Center at Carrollton, where he was pronounced dead.

Lt. Darren Brockway of The Colony police said the medical examiner’s ruling is consistent with police conclusions about the death.

“He’d gotten in trouble at school and panicked,” Brockway said. “He just felt there was no other way out.”

There had been speculation that Montana watched a television show about teen suicide the night before his death and was copying what he saw with no real intention to kill himself.

“We ruled that out as an option after talking to his parents,” Brockway said. “He didn’t watch that show.”

Also Online
01/25/10: Friends, family stunned by apparent suicide of 9-year-old boy

Link: Leave your condolences for the family of Montana Lance

Still, experts say children as young as Montana may not fully comprehend the consequences of their actions. A suicidal act may be a spur-of-the-moment act, like an outburst or a tantrum, they say.

“It was more of a conscious decision he made in a moment of high anxiety,” Brockway said.

A spokesman for the Lance family could not be reached for comment Thursday. A police report says Montana’s father had insisted the death was accidental.

Brockway said Montana had been upset on the day of his death after he was sent to the office for misbehaving in class. He locked himself in the school nurse’s restroom and didn’t come out.

After about 10 minutes, the nurse got a key to open the door and found the child unconscious.

Montana had attached the buckle of a brown cloth belt to a hook of a device used to help disabled people use the restroom, according to a police report. He was found with the belt around his neck with his feet off the floor. Police found no notes or messages.

He had been taking medication for mood swings and for attention deficit hyperactivity disorder, and had been having suicidal thoughts for about two years, the police report states.

In 2007, Montana’s parents, Jason and Debbie Lance, sought treatment for their son for ADHD.

In 2008, they told the doctor that the boy had been talking about committing suicide, and he was referred to a psychiatrist, according to the police report.

After Montana’s death, Child Protective Services opened an investigation to determine whether abuse or neglect were contributing factors.

That investigation has not been completed, but the family’s other two children have not been removed from the home, CPS spokeswoman Marissa Gonzales said.

Gonzales said CPS has had no prior involvement with the Lances and routinely investigates child fatalities.

With the medical examiner’s ruling, police plan to close their investigation with no charges filed, Brockway said.

1,153 total views, 1 views today